Indications and complications of transfusions in sickle cell disease

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 358-364

  Smith Whitley, Kim ^a   Thompson, Alexis A ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Alloimmunization; Red cell transfusion indications; Sickle cell disease; Transfusional iron overload

Indexed keywords

DEFERASIROX; DEFERIPRONE; HEMOGLOBIN; HYDROXYUREA;

ACUTE CHEST SYNDROME; ALLOIMMUNIZATION; BLOOD GROUP TYPING; BLOOD STORAGE; BLOOD TRANSFUSION REACTION; BLOODSTREAM INFECTION; BRAIN INFARCTION; DISEASE EXACERBATION; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; ETHNICITY; GASTROINTESTINAL DISEASE; HEMAGGLUTINATION TEST; HEMOSIDEROSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; PRIORITY JOURNAL; RASH; RETICULOCYTE COUNT; REVIEW; RISK MANAGEMENT; SICKLE CELL ANEMIA; SPLENECTOMY; SPLENOMEGALY; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS;

EID: 84862240717     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24179     Document Type: Review

References (73)

1. Rosse WF, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431- 1437.
2. Vichinsky EP, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617- 1621.
3. Aygun B, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37- 43.
4. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5- 11.
5. Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353: 2769- 2778.
6. Hillyer CD, Blumberg N, Glynn SA, et al. Transfusion recipient epidemiology and outcomes research: Possibilities for the future. Transfusion 2008; 48: 1530- 1537.
7. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol 2001; 38: 5- 13.
8. Kinney TR, Ware RE, Schultz WH, et al. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr 1990; 117: 194- 199.
9. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86: 776- 783.
10. Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004; 103: 422- 427.
11. Ohene-Frempong K. Stroke in sickle cell disease: Demographic, clinical, and therapeutic considerations. Semin Hematol 1991; 28: 213- 219.
12. Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med 1978; 65: 461- 471.
13. Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002; 140: 348- 354.
14. Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 2006; 149: 710- 712.
15. Fullerton HJ, Adams RJ, Zhao S, et al. Declining stroke rates in Californian children with sickle cell disease. Blood 2004; 104: 336- 339.
16. Enninful-Eghan H, Moore RH, Ichord R, et al. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J Pediatr 2010; 157: 479- 484.
17. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011; 117: 772- 779.
18. Gyang E, Yeom K, Hoppe C, et al. Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease. Am J Hematol 2011; 86: 104- 106.
19. Brousse V, Hertz-Pannier L, Consigny Y, et al. Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease? Ann Hematol 2009; 88: 785- 788.
20. Bishop S, Matheus MG, Abboud MR, et al. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. Blood Cells Mol Dis 2011; 47: 125- 128.
21. Aygun B, McMurray MA, Schultz WH, et al. Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol 2009; 145: 524- 528.
22. McCarville MB, Rogers ZR, Sarnaik S. et al. Effects of chronic transfusions on abdominal sonorgraphic abnormalities in children with sickle cell anemia. J Pediatr 2012; 160: 281- 285.
23. Ware RE, Schultz WH, Yovetich N, et al. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer 2011; 57: 1011- 1017.
24. Ware RE, Helms RW. For the SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012; 119: 3925- 3932.
25. Emre U, Miller ST, Gutierez M, et al. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995; 127: 901- 904.
26. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333: 206- 213.
27. Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child 1988; 142: 178- 182.
28. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94: 1550- 1554.
29. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994; 125: 909- 911.
30. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139: 785- 789.
31. Hankins J, Jeng M, Harris S, et al. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol 2005; 27: 158- 161.
32. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91: 1000- 1005.
33. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: Frequency, characteristics and significance. Br J Haematol 1999; 104: 189- 194.
34. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: A multicenter transfusion trial. Transfusion 2001; 41: 1086- 1092.
35. Castro O, Sandler SG, Houston-Yu P, et al. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: Theoretical and practical implications. Transfusion 2002; 42: 684- 690.
36. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: A review of a 14-year experience from a single center. Transfusion 2011; 51: 1732- 1739.
37. Venkateswaran L, Teruya J, Bustillos C, et al. Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease. Pediatr Blood Cancer 2011; 57: 294- 296.
38. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: A survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129: 190- 193.
39. Afenyi-Annan A, Brecher ME. Pre-transfusion phenotype matching for sickle cell disease patients. Transfusion 2004; 44: 619- 620.
40. Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 111: e661- e665.
41. Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: Evidence for a distinct population of immunologic responders. Blood 2008; 112: 2546- 2553.
42. Zimring JC, Hendrickson JE. The role of inflammation in alloimmunization to antigens on transfused red blood cells. Curr Opin Hematol 2008; 15: 631- 635.
43. Hendrickson JE, Chadwick TE, Roback JD, et al. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood 2007; 110: 2736- 2743.
44. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. Am J Med Sci 2010; 339: 266- 269.
45. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 2011; 96: 801- 807.
46. Vichinsky EP, Butensky, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80: 70- 74.
47. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol 2007; 82: 255- 265.
48. Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 2009; 114: 4632- 4638.
49. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96: 76- 79.
50. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: 1460- 1465.
51. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501- 508.
52. Inati A, Khoriaty E, Musallam KM. Iron in sickle-cell disease: What have we learned over the years? Pediatr Blood Cancer 2011; 56: 182- 190.
53. Hankins JS, Smeltzer MP, McCarville MB, et al. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. Eur J Haematol 2010; 85: 51- 57.
54. Flanagan JM, Steward S, Hankins JS, et al. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol 2009; 84: 328- 334.
55. Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005; 84: 434- 440.
56. ElAlfy MS, Sari TT, Lee CL, et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010; 32: 601- 605.
57. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154: 387- 397.
58. Lucania G, Vitrano A, Filosa A, et al. Chelation treatment in sickle-cell-anaemia: Much ado about nothing? Br J Haematol 2011; 154: 545- 555.
59. Reid ME. Transfusion in the age of molecular diagnostics. Hematol Am Soc Hematol Edu Prog 2009; 171- 177.
60. Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood 2009; 114: 248- 256.
61. Wilkinson K, Harris S, Gaur P, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 2012; 52: 381- 388.
62. Westhoff CM, Sloan SR. Molecular genotyping in transfusion medicine. Clin Chem 2008; 54: 1948- 1950.
63. Chou ST, Westhoff CM. The role of molecular immunohematology in sickle cell disease. Transfus Apher Sci 2011; 44: 73- 79.
64. Chou ST, Westhoff CM. Molecular biology of the Rh system: Clinical considerations for transfusion in sickle cell disease. Hematol Am Soc Hematol Edu Prog 2009; 178- 184.
65. Sesok-Pizzini DA, Friedman DF, Smith-Whitley K, et al. Transfusion support of patients with sickle cell disease at the Children's Hospital of Philadelphia. Immunohematology 2006; 22: 121- 125.
66. Hillyer KL, Hare VW, Josephson CD, et al. Partners for life: The transfusion program for patients with sickle cell disease offered at the American Red Cross Blood Services, Southern Region, Atlanta, Georgia. Immunohematology 2006; 22: 108- 111.
67. Isaak EJ, LeChien B, Lindsey T, et al. The Charles Drew program in Missouri: A description of a partnership among a blood center and several hospitals to address the care of patients with sickle cell disease. Immunohematology 2006; 22: 112- 116.
68. Hod EA, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood 2010; 115: 4284- 4292.
69. Friedman DF, Lukas MB, Jawad A, et al. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood 1996; 88: 3216- 3222.
70. Spinella PC, Dressler A, Tucci M, et al. Survey of transfusion policies at US and Canadian children's hospitals in 2008 and 2009. Transfusion 2010; 50: 2328- 2335.
71. Afenyi-Annan A, Willis MS, Konrad TR, et al. Blood bank management of sickle cell patients at comprehensive sickle cell centers. Transfusion 2007; 47: 2089- 2097.
72. Schuetz AN, Hillyer KL, Roback JD, et al. Leukoreduction filtration of blood with sickle cell trait. Transfus Med Rev 2004; 18: 168- 176.
73. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol 2001; 38: 14- 22.